A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Trial details
- Registry ID
- NCT06051409
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)NCT06051409 | Ascentage Pharma Group Inc. | Phase 3 | Recruiting | 2027-12-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |